A High-Throughput Platform for COVID-19 Serodiagnosis, Vaccine Evaluation, and Drug Discovery

NIH RePORTER · NIH · R01 · $699,894 · view on reporter.nih.gov ↗

Abstract

ABSTRACT In response to the current COVID-19 pandemic, it is of paramount importance to rapidly diagnose infections and to develop countermeasures. This project aims to build a high-throughput platform for rapid COVID-19 serodiagnosis, vaccine evaluation, and therapeutics development.

Key facts

NIH application ID: 10142203
Project number: 3R01AI134907-03S2
Recipient: UNIVERSITY OF TEXAS MED BR GALVESTON
Principal Investigator: Ricardo Rajsbaum
Activity code: R01
Funding institute: NIH
Fiscal year: 2020
Award amount: $699,894
Award type: 3
Project period: 2020-05-01 → 2021-04-30